BCV
KPTI icon

Banque Cantonale Vaudoise’s Karyopharm Therapeutics KPTI Stock Holding History

Banque Cantonale Vaudoise’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$153K – 1202
2022
Q4 		$153K Hold
30
– – 0.01% 774
2022
Q3 		$247K Hold
30
– – 0.01% 662
2022
Q2 		$203K Hold
30
– – 0.01% 734
2022
Q1 		$331K Buy
30
+15
+100% +$1.87K 0.01% 668
2021
Q4 		$141K Hold
15
– – 0.01% 898
2021
Q3 		$128K Buy
+15
New +$1.56K 0.01% 893

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Banque Cantonale Vaudoise's KPTI Position: Q3 2024 in Review

Banque Cantonale Vaudoise sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,667 shares — an estimated $22K sold.

Banque Cantonale Vaudoise first reported a position in KPTI in Q3 2020 and held it in 13 quarters. The position peaked at $310K in Q4 2020. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Banque Cantonale Vaudoise reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 1,667 Karyopharm Therapeutics shares in Q3 2024, an estimated $22K.
  • Banque Cantonale Vaudoise first reported a position in Karyopharm Therapeutics in Q3 2020 and held it in 13 quarters.
  • Banque Cantonale Vaudoise's Karyopharm Therapeutics position peaked at $310K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2024, filed 8 Nov 2024.